Clinical Outcomes After Treatment With RestrataTM Wound Matrix in Diabetic Foot Ulcers (DFU)

Diabetic Foot Ulcer Clinical Trial

Official title:

Clinical Outcomes After Treatment With RestrataTM Wound Matrix in Diabetic Foot Ulcers (DFU) A Case Series of Initial Effectiveness and Safety Measures

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03312595
• Other study ID #: 17-RES-001
• Status: Completed
• Phase: N/A
• Start date: September 14, 2017
• Est. completion date: July 30, 2018

Study information

• Verified date: April 2021
• Source: Acera Surgical, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to determine the outcomes of patients who receive a certain type of skin substitute called RestrataTM Wound Matrix (Restrata™). Results of this study may be used to make decisions on whether to conduct additional studies on this particular wound matrix product. RestrataTM has been cleared by the Food and Drug Administration for use in certain types of ulcer treatments, including the type that will be part of this study (diabetic foot ulcers).

Description:

Control Group: None (Utilize historical / published data on outcomes using standard of care) Test Group: Treatment of DFUs with RestrataTM Wound Matrix Study Type: Interventional Study Design: Allocation: Non-randomized Endpoint Classification: Efficacy Intervention Model: Direct assignment Masking: Single Blind (Subject) Primary Purpose: Treatment

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: July 30, 2018
• Est. primary completion date: July 15, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or female age 18 or older
• Patient's ulcer must be diabetic in origin, located at least in part on the plantar surface and larger than 1cm2 after the run-in period. Debridement will be done prior to randomization. Subject's informed consent for participating in this study, must be obtained prior to proceeding with sharp debridement
• Patients with Type 1 or Type 2 diabetes (criteria for the diagnosis of diabetes mellitus per ADA).
• Ulcer must be present for a minimum of four weeks before enrollment/randomization, with documented failure of prior treatment to heal the wound. A two-week run in period will precede enrollment/randomization in the trial to document the indolent nature of the patients selected
• Patient does not exhibit clinical signs / symptoms of infection upon gross observation (at least 3 of the following: pain, redness, purulence, exudate, temperature) or have been diagnosed with an active infection at time of screening
• Patient is willing to provide informed consent and is willing to participate in all procedures and follow up evaluations necessary to complete the study
• Patient has adequate control of diabetes, as demonstrated by one of the following

within 30 days of screening:

• HbA1c < 12%
• Serum Creatinine < 3.0mg/dl
• Patient has adequate circulation to the affected extremity, as demonstrated by one of

the following within the past 60 days of the first screening visit:

• Dorsum transcutaneous oxygen test (TcPO2) with results =30mmHg, OR
• ABIs with results of =0.7 and =1.5, OR
• Doppler arterial waveforms, which are triphasic or biphasic at the ankle of affected leg

Exclusion Criteria:

• Patients presenting with an ulcer probing to bone (UT Grade IIIA-D)
• Patients whose index diabetic foot ulcers are greater than 25cm2
• Patient has an additional wound within 3cm of the study wound
• Patients not in reasonable metabolic control
• Patients with a known history of poor compliance with medical treatments
• Patients who have been previously enrolled into this study, or are presently participating in a clinical trial with DFU indications
• Patients with known or suspected local skin malignancy to the index diabetic ulcer
• Patients diagnosed with autoimmune connective tissues diseases
• Patients that have received a graft material on the study ulcer within the previous 30 days
• Patients who are pregnant or breast feeding
• Patients who are taking medications that are considered immune system modulator
• Study wound has closed > 30% over the two-week run-in period
• Patients with a known allergy to resorbable suture materials

Related Conditions & MeSH terms

• Diabetic Foot
• Diabetic Foot Ulcer
• Foot Ulcer
• Ulcer

Intervention

Device:
• Restrata TM Wound Matrix
The RestrataTM Wound Matrix is a sterile, single use device intended for use in local management of wounds

Locations

Country	Name	City	State
United States	Richard C. Galperin, DPM	Dallas	Texas
United States	Advanced Foot Care And Clinical Research Center	Fresno	California
United States	Associated Foot & Ankle Specialists	Phoenix	Arizona
United States	Arizona Reginal Medical Research	Tucson	Arizona
United States	SAVAHCS	Tucson	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
Acera Surgical, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants With Wound Closed	from baseline at week 0 to 14 weeks	Up to 14 weeks
Secondary	Change in Wound Area From Baseline	Wound area measurements will be made via tracing acetate every week for 14 weeks.	Baseline and weekly for up to 14 weeks
Secondary	Time to Wound Closure	The number of weeks until complete closure is first identified will be determined for each patient who has been deemed completely closed within the 14 week treatment period.	Baseline up to 14 weeks